ABSTRACT: CUSP9 treatment protocol for recurrent glioblastoma was published one year ago. We now present a slight modification, designated CUSP9*. CUSP9* drugs- aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, sertraline, ritonavir, are all widely approved by regulatory authorities, marketed for non-cancer indications. Each drug inhibits one ... Continue Reading
glioblastoma
STUDY: DR-06 REACTIVE OXYGEN SPECIES MEDIATE THERAPEUTIC RESPONSE AND RESISTANCE IN GLIOBLASTOMA
ABSTRACT: Glioblastoma (GBM) resistance to therapy is the most common cause of tumor recurrence, which is ultimately fatal in 90 percent of the patients five years after initial diagnosis. A subpopulation of tumor cells with stem like properties are specifically endowed to resist or adapt to the standard therapies (e.g, radiation, chemotherapy) and lead to tumor resistance. ... Continue Reading
STUDY: Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression
ABSTRACT: Herein we evaluate the involvement of the TRPV2 channel, belonging to the Transient Receptor Potential Vanilloid channel family (TRPVs), in development and progression of different tumor types. In normal cells, the activation of TRPV2 channels by growth factors, hormones, and endocannabinoids induces a translocation of the receptor from the endosomal compartment to ... Continue Reading
STUDY: Local Delivery of Cannabinoid-Loaded Microparticles Inhibits Tumor Growth in a Murine Xenograft Model of Glioblastoma Multiforme
ABSTRACT: Cannabinoids, the active components of marijuana and their derivatives, are currently investigated due to their potential therapeutic application for the management of many different diseases, including cancer. Specifically, Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) – the two major ingredients of marijuana – have been shown to inhibit tumor growth in a ... Continue Reading